Eintrag weiter verarbeiten
Pathogenetic evaluation of the ocular surface drug correction in patients before LASIK
Gespeichert in:
| Zeitschriftentitel: | Acta Ophthalmologica |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Acta Ophthalmologica, 90, 2012, s249, S. 0-0 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| Zusammenfassung: | <jats:title>Abstract</jats:title><jats:p><jats:bold>Purpose</jats:bold> Development and evaluation of the method of optimizing the ocular surface before the refractive intervention.</jats:p><jats:p><jats:bold>Methods</jats:bold> Overall, 485 patients were enrolled in this case‐control study. Assessed the ocular surface, tear film and tear production before and after optimization of preoperative LASIK patients in 4 groups. Group 1 (A) ‐ high myopia ‐ (97), aged 18 to 35 years, group 2 (B) ‐ medium myopia – (145), aged 18 to 35 years, group 3 (C) ‐ myopia medium or high – (73), older than 35 years, group 4 (D) ‐ hypermetropia medium or high ‐ (49), older than 35 years. The criteria for preoperative drug correction of refractive surgery to the stage were the following diagnostic blocks: clinical data in diagnosis of dry eye and corneal status, corneal thickness, the definition of clinical refraction, including patient age, antioxidant and immune activity of tears.</jats:p><jats:p><jats:bold>Results</jats:bold> The use of a preparation containing hydroxypropylguar and sorbitol in groups A and D, and a preparation containing hydroxyproylguar in groups B and C before LASIK reduces the number of complications refractive surgery.</jats:p><jats:p><jats:bold>Conclusion</jats:bold> The correlation between the choice of ocular surface drug correction and the evaluation of the Norn, Lipkof, cornea vital coloring tests, cornea thickness (mm), the type of refractive error and degree of change (and its degree of myopia), the patient's age (35 and older than 35 years of age), antioxidant and immune activity of tears (the concentration of peroxyredoxin 6 (PRDX6), the presence or absence of gamma globulin).</jats:p> |
|---|---|
| Umfang: | 0-0 |
| ISSN: |
1755-375X
1755-3768 |
| DOI: | 10.1111/j.1755-3768.2012.4442.x |